Breast cancer susceptibility associated with rs1219648 (fibroblast growth factor receptor 2) and postmenopausal hormone therapy use in a population-based United States study

Menopause

Volumn 20, Issue 3, 2013, Pages 354-358

  Andersen, Shaneda Warren ^a,b   Trentham Dietz, Amy ^a,b   Figueroa, Jonine D ^c   Titus, Linda J ^d   Cai, Qiuyin ^e   Long, Jirong ^e   Hampton, John M ^a   Egan, Kathleen M ^f   Newcomb, Polly A ^a,g  

^a UNIVERSITY OF WISCONSIN   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d DARTMOUTH MEDICAL SCHOOL   (United States)

^e VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^f H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^g Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Breast cancer; Epidemiology; Gene environment interaction; Genetics; Hormone therapy

Indexed keywords

DNA; ESTROGEN; FIBROBLAST GROWTH FACTOR RECEPTOR 2; GESTAGEN;

ADULT; AGED; ALLELE; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RISK; CANCER SUSCEPTIBILITY; CLINICAL PROTOCOL; COMMUNITY; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; HYPOTHESIS; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; POPULATION BASED CASE CONTROL STUDY; POSTMENOPAUSE; RISK; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE; STRUCTURED INTERVIEW; TELECONSULTATION; UNITED STATES;

EID: 85027935283     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/GME.0b013e318268ca46     Document Type: Article

References (18)

1. Luqmani YA, Graham M, Coombes RC. Expression of basic fibroblast growth factor, FGFR1 and FGFR2 in normal and malignant human breast, and comparison with other normal tissues. Br J Cancer 1992; 66: 273-280.
2. Hunter DJ, Kraft P, Jacobs KB, et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet 2007;39: 870-874.
3. Easton DF, Pooley KA, Dunning AM, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007;447: 1087-1093.
4. Gold B, Kirchhoff T, Stefanov S, et al. Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33. Proc Natl Acad Sci U S A 2008;105: 4340-4345.
5. Meyer KB, Maia AT, O'Reilly M, et al. Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer. PLoS Biol 2008;6: e108.
6. Liang J, Chen P, Hu Z, et al. Genetic variants in fibroblast growth factor receptor 2 (FGFR2) contribute to susceptibility of breast cancer in Chinese women. Carcinogenesis 2008;29: 2341-2346.
7. Garcia-Closas M, Chanock S. Genetic susceptibility loci for breast cancer by estrogen receptor status. Clin Cancer Res 2008;14: 8000-8009.
8. Garcia-Closas M, Hall P, Nevanlinna H, et al. Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet 2008;4: e1000054.
9. Rebbeck TR, DeMichele A, Tran TV, et al. Hormone-dependent effects of FGFR2 and MAP3K1 in breast cancer susceptibility in a populationbased sample of post-menopausal African-American and European- American women. Carcinogenesis 2009;30: 269-274.
10. Prentice RL, Huang Y, Hinds DA, et al. Variation in the FGFR2 gene and the effects of postmenopausal hormone therapy on invasive breast cancer. Cancer Epidemiol Biomarkers Prev 2009;18: 3079-3085.
11. Travis RC, Reeves GK, Green J, et al. Gene-environment interactions in 7610 women with breast cancer: prospective evidence from the Million Women Study. Lancet 2010;375: 2143-2151.
12. Garcia-Closas M, Egan KM, Abruzzo J, et al. Collection of genomic DNA from adults in epidemiological studies by buccal cytobrush and mouthwash. Cancer Epidemiol Biomarkers Prev 2001;10: 687-696.
13. Garcia-Closas M, Egan KM, Newcomb PA, et al. Polymorphisms in DNA double-strand break repair genes and risk of breast cancer: two population-based studies in USA and Poland, and meta-analyses. Hum Genet 2006;119: 376-388.
14. Sprague BL, Trentham-Dietz A, Garcia-Closas M, et al. Genetic variation in TP53 and risk of breast cancer in a population-based case control study. Carcinogenesis 2007;28: 1680-1686.
15. Udler MS, Meyer KB, Pooley KA, et al. FGFR2 variants and breast cancer risk: fine-scale mapping using African American studies and analysis of chromatin conformation. Hum Mol Genet 2009;18: 1692-1703.
16. Raskin L, Pinchev M, Arad C, et al. FGFR2 is a breast cancer susceptibility gene in Jewish and Arab Israeli populations. Cancer Epidemiol Biomarkers Prev 2008;17: 1060-1065.
17. Stacey SN, Manolescu A, Sulem P, et al. Common variants on chromosome 5p12 confer susceptibility to estrogen receptorYpositive breast cancer. Nat Genet 2008;40: 703-706.
18. Anderson WF, Chatterjee N, Ershler WB, Brawley OW. Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat 2002;76: 27-36.